Caribou Biosciences, Inc. (CRBU) Stock Grade

About Caribou Biosciences, Inc.'s fundamentals

Caribou Biosciences is a small-cap biotech company with a market capitalization of $122.0 million that is still in its development phase, as evidenced by its net loss in the latest annual period and extreme negative net margin of -1327.4%. The company showed modest revenue growth of 11.7% year-over-year, indicating early commercial traction despite operating losses. With no dividend and typical biotech metrics like P/E ratio and return on equity being unavailable due to unprofitability, the company's financial position reflects the capital-intensive nature of drug development where profitability remains distant.